space is not an issue.
3 Information submitted to a trial registry is the responsibility of the registrant, who agrees before registration that they are an appropriate representative of the trial sponsor. Hence, trial registries cannot "request" 3 that all outcomes are listed in the registration record because there is no way of verifying what outcomes have been prespecifi ed when full protocols are not made public.
Trialists should thus give due attention to their trial's registration record and update it regularly. Too often, this task is seen as administrative rather than scientific and is frequently delegated to junior team members, increasing the risk of important details, such as the inclusion of all relevant outcome information, being inadvertently missed. It is the trialists' responsibility to regularly update their registration record, ensuring that they adhere to current standards of disclosure over (the often long) trial timeline.
Trial registries and the COMPare project are both trying to reduce the potential bias introduced by selective outcome reporting. The GAS trialists have conceded that they did not fully update their registration record over the 10 years of the trial to include the level of detail now expected. We have acknowledged that ANZCTR's standards for outcome reporting are now higher than they were when the GAS trial was fi rst registered in 2006. I hope the COMPare team will also concede that although their approach to expose outcome switching undoubtedly has high impact, the collateral damage caused to well meaning trialists along the way is something worth considering. 
Control of gonorrhoea and chlamydia in the UK
Evidence is growing of high-level azithromycin resistance to gonorrhoea in the UK, leading to claims that the infection might become untreatable.
1,2
Increased surveillance has been suggested as a control measure but questions remain as to how this resistance has developed.
The history of antibiotic gonococcal resistance is well documented and seems to be related to subtherapeutic dosing often by patients with low-cost pills, mainly in Asia. However, there is now a clear parallel to this scenario in the UK with respect to azithromycin, albeit through a diff erent mechanism. In 2003, the national UK chlamydia screening programme started, which involved an expansion of tests for chlamydia and treatment with 1 g of azithromycin in most cases. Gonorrhoea was not tested for and it is likely that many definitive and incubating gonorrhoea cases were given 1 g of azithromycin. As azithromycin has a long half-life, many such cases could have been exposed to subtherapeutic doses of the drug. A further relevant factor was the introduction of 1 g of azithromycin to treat gonorrhoea together with ceftriaxone in 2013 to tackle the increasing drift of resistance to ceftriaxone.
3
In view of the rapid emergence of these azithromycin-resistant strains, an alternative strategy for gonorrhoea and chlamydia control would be to curtail the use of azithromycin. Chlamydia could then be treated very successfully with doxycycline, as in the past, whereas for gonorrhoea, the dose of ceftriaxone could be increased to 1 g and would be cost neutral as the current 500 mg dose entails use of a 1 g vial.
I declare no competing interests. Article, the results for mean EQ-5D utility score should have been: "For RBL the mean at day 1 was 0·84 (SD 0·19) and at day 7 it was 0·92 (0·15)…with the mean being 0·76 (0·22) at day 1 and 0·83 (0·18) at day 7. The adjusted diff erence in means were 0·08 (95% CI 0·04-0·13; p<0·001) at day 1 and 0·08 (0·05-0·12; p<0·001) at day 7. The mean health utility was nearly similar with no statistical diff erences between the two groups (and above baseline values) at all timepoints from day 21 onwards." In the Discussion section, the following sentence has been clarifi ed: "Even if a diff erence in recurrence is assumed, (ie, single RBL procedure vs HAL) the cost-eff ectiveness in terms of cost per recurrence avoided is approximately £5000". This correction has been made to the online version as of July 21, 2016, and the printed version is correct.
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